References
- Mizrak D, Brittan M, Alison M. CD133: molecule of the moment. J Pathol 2008;214:3–9.
- Corbeil D, Roper K, Hellwig A, Tavian M, Miraglia S, Watt SM, The human AC133 hematopoietic stem cell antigen is also expressed in epithelial cells and targeted to plasma membrane protrusions. J Biol Chem 2000;275:5512–20.
- O'Brien C, Pollett A, Gallinger S, Dick, JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007;445:106–10.
- Ricci-Vitiani L, Lombardi D, Signore M, Biffoni M, Pallini R, Parati E, Identification and expansion of human colon-cancer-initiating cells. Nature 2007;445:111–15.
- Shmelkov S, Butler J, Hooper A, Hormigo A, Kushner J, Milde T, CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors. J Clin Invest 2008;118:2111–20.
- Yang K, Chen X, Zhang B, Yang C, Chen HN, Chen ZX, Is CD133 a biomarker for cancer stem cells of colorectal cancer and brain tumors? A meta-analysis. Int J Biol Markers 2011;26:173–80.
- Horst D, Kriegl L, Engel J, Kirchner T, Jung A. Prognostic significance of the cancer stem cell markers CD133, CD44, and CD166 in colorectal cancer. Cancer Invest 2009;27:844–50.
- Horst D, Kriegl L, Engel J, Kirchner T, Jung A. CD133 expression is an independent prognostic marker for low survival in colorectal cancer. Br J Cancer 2008;99:1285–9.
- Horst D, Scheel S, Liebmann S, Neumann J, Maatz S, Kirchner T, Jung A. The cancer stem cell marker CD133 has high prognostic impact but unknown functional relevance for the metastasis of human colon cancer. J Pathol 2009;219:427–34.
- Kojima M, Ishii G, Atsumi N, Fujii S, Saito N, Ochiai A. Immunohistochemical detection of CD133 expression in colorectal cancer: a clinicopathological study. Cancer Sci 2008;99:1578–83.
- Li C, Li B, Liang Y, Peng RQ, Ding Y, Xu DZ, Higher percentage of CD133+ cells is associated with poor prognosis in colon carcinoma patients with stage IIIB. J Transl Med 2009;7:56.
- O'Connell J, Maggard M, Ko C. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 2004;96:1420–5.
- Reggiani Bonetti L, Di Gregorio C, De Gaetani C, Pezzi A, Barresi G, Barresi V, Roncucci L, Ponz de Leon M. Lymph node micrometastasis and survival of patients with Stage I (Dukes' A) colorectal carcinoma. Scand J Gastroenterol 2011;46:881–6.
- Arena V, Caredda V, Cufino V, Stigliano E, Scaldaferri F, Gasbarrini A, Cittadini A, Sgambato A. Differential CD133 expression pattern during mouse colon tumorigenesis. Anticancer Res 2011;31:4273–5.
- Sgambato A, De Paola B, Migaldi M, Di Salvatore M, Rettino A, Rossi G, Dystroglycan Expression is Reduced During Prostate Tumorigenesis and is Regulated by Androgens in Prostate Cancer Cells. J Cell Physiol 2007;213:528–39.
- Vermeulen L, Sprick M, Kemper K, Medema JP. Cancer stem cells – old concepts, new insights. Cell Death Differ 2008;15:947–58.
- Cutait R, Alves V, Lopes LC, Cutait DE, Borges JL, Singer J, da Silva JH, Goffi FS. Restaging of colorectal cancer based on the identification of lymph node micrometastases through immunoperoxidase staining of CEA and cytokeratin. Dis Colon Rectum 1999;34:917–20.
- Lee M, Hong C, Yoon S, Lim SB, Park KJ, Lee MJ, Kim WH, Park JG. Isolated tumor cells in lymph nodes are not a prognostic marker for patients with stage I and stage II colorectal cancer. J Surg Oncol 2006;93:13–18.
- Oberg A, Stenling R, Tavelin B, Lindmark G. Are lymph node micrometastases of any clinical significance in Dukes' Stages A and B colorectal cancer? Dis Colon Rectum 1998;41:1244–9.
- van Schaik P, Hermans E, van der Linden J, Pruijt JR, Ernst MF, Bosscha K. Micro-metastases in stages I and II colon cancer are a predictor of the development of distant metastases and worse disease-free survival. Eur J Surg Oncol 2009;35:492–6.